Atara Biotherapeutics Inc.
03/12/2026 | Press release | Distributed by Public on 03/12/2026 06:10
Material Event (Form 8-K)
Item 8.01 Other Events.
On March 12, 2026, Atara Biotherapeutics, Inc. (the "Company") issued a press release titled "Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel" announcing that the Type A meeting with the U.S. Food and Drug Administration (the "FDA") to discuss the Complete Response Letter for the EBVALLO™ Biologics License Application issued on January 9, 2026 has been scheduled.
A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
d) Exhibits.
|
Exhibit No. |
Description |
|
|
99.1 |
Press Release, dated March 12, 2026 |
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
Atara Biotherapeutics Inc. published this content on March 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 12, 2026 at 12:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]